ESR1 and breast carcinoma: Subsequently, the effect of FGF stimulation on the anti-proliferative activity of fulvestrant and palbociclib + fulvestrant was evaluated in vitro using three ER+ breast cancer cell lines: MCF7, ZR-75-1, and HCC1428.